CN111448314B - 根据可开发性选择真核细胞展示系统中的多肽药物 - Google Patents

根据可开发性选择真核细胞展示系统中的多肽药物 Download PDF

Info

Publication number
CN111448314B
CN111448314B CN201880079095.7A CN201880079095A CN111448314B CN 111448314 B CN111448314 B CN 111448314B CN 201880079095 A CN201880079095 A CN 201880079095A CN 111448314 B CN111448314 B CN 111448314B
Authority
CN
China
Prior art keywords
binding agent
binding
clones
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880079095.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111448314A (zh
Inventor
J·麦考夫迪
R·佩雷拉
M·R·戴森
K·帕特赫本
J·L·锡尔加宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iontas Ltd
Original Assignee
Iontas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iontas Ltd filed Critical Iontas Ltd
Publication of CN111448314A publication Critical patent/CN111448314A/zh
Application granted granted Critical
Publication of CN111448314B publication Critical patent/CN111448314B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880079095.7A 2017-12-06 2018-12-05 根据可开发性选择真核细胞展示系统中的多肽药物 Active CN111448314B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1720351.4 2017-12-06
GBGB1720351.4A GB201720351D0 (en) 2017-12-06 2017-12-06 Selecting for developability in drug discovery
PCT/EP2018/083698 WO2019110691A1 (en) 2017-12-06 2018-12-05 Selecting for developability of polypeptide drugs in eukaryotic cell display systems

Publications (2)

Publication Number Publication Date
CN111448314A CN111448314A (zh) 2020-07-24
CN111448314B true CN111448314B (zh) 2024-10-18

Family

ID=60950392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880079095.7A Active CN111448314B (zh) 2017-12-06 2018-12-05 根据可开发性选择真核细胞展示系统中的多肽药物

Country Status (8)

Country Link
US (1) US11499150B2 (enExample)
EP (1) EP3720959A1 (enExample)
JP (2) JP7744746B2 (enExample)
CN (1) CN111448314B (enExample)
AU (1) AU2018379426B2 (enExample)
CA (1) CA3083571A1 (enExample)
GB (1) GB201720351D0 (enExample)
WO (1) WO2019110691A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3786292A1 (en) * 2016-01-08 2021-03-03 Maxion Therapeutics Limited Binding members with altered diversity scaffold domains
GB201720162D0 (en) * 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
WO2021018114A1 (zh) * 2019-07-30 2021-02-04 中山康方生物医药有限公司 抗人p40蛋白域抗体及其用途
GB202014851D0 (en) 2020-09-21 2020-11-04 Iontas Ltd SARS-COV-2 antibodies
CN118525099A (zh) 2021-08-25 2024-08-20 艾恩塔斯有限公司 真核细胞中表达的蛋白质变体文库的制备
WO2023039528A1 (en) * 2021-09-10 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nanobody-mediated control of gene expression and epigenetic memory
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
EP4646476A1 (en) 2023-01-06 2025-11-12 Seismic Therapeutic, Inc. Protease variants and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CN106574264A (zh) * 2014-05-02 2017-04-19 艾恩塔斯有限公司 在真核细胞中表达的蛋白质变体文库的制备及用于选择结合分子的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485943B2 (en) * 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
JP2010213725A (ja) * 1998-01-20 2010-09-30 Univ Illinois タンパク質の酵母細胞表面ディスプレイおよびその使用
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
PT2702160T (pt) 2011-04-27 2020-07-30 Amyris Inc Métodos para modificação genómica
EP2794662A1 (en) 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CN106574264A (zh) * 2014-05-02 2017-04-19 艾恩塔斯有限公司 在真核细胞中表达的蛋白质变体文库的制备及用于选择结合分子的用途

Also Published As

Publication number Publication date
US20210163923A1 (en) 2021-06-03
AU2018379426A1 (en) 2020-06-18
US11499150B2 (en) 2022-11-15
GB201720351D0 (en) 2018-01-17
CN111448314A (zh) 2020-07-24
EP3720959A1 (en) 2020-10-14
JP7744746B2 (ja) 2025-09-26
WO2019110691A1 (en) 2019-06-13
CA3083571A1 (en) 2019-06-13
JP2021509010A (ja) 2021-03-18
JP2024009895A (ja) 2024-01-23
AU2018379426B2 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
CN111448314B (zh) 根据可开发性选择真核细胞展示系统中的多肽药物
KR102282691B1 (ko) 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법
CN108473987B (zh) 具有改变的多样性支架结构域的结合成员
CN106459220B (zh) 适用于高通量筛选的新的双特异性形式
RU2569187C2 (ru) Коллекция и способы ее применения
JP2021524249A (ja) 抗ｃｄ３抗体及びその使用
McCafferty et al. Identification of optimal protein binders through the use of large genetically encoded display libraries
JP7747645B2 (ja) グリピカン－３（ｇｐｃ３）を標的化する抗体及びキメラ抗原受容体並びにその使用方法
CN107108750A (zh) 细胞表面上非共价含Fc结构域的蛋白质展示的方法
Chen et al. Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains
JP2025524923A (ja) クローディン－６結合部分及びその使用
Jung et al. Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding
JP6918399B2 (ja) 抗体ナイーブライブラリーを生成する方法、前記ライブラリー及びその用途
CN114829407B (zh) 利用哺乳动物展示筛选FcγR特异性结合Fc
JP2024522092A (ja) Ｆｃ受容体に対する親和性の増強および熱安定性の改善を伴うＦｃバリアント
US11414493B2 (en) Aglycosylated antibody Fc region for treating cancer
US20130045895A1 (en) Binding domains
KR20220087488A (ko) Pd-l1 결합 분자
JP2025533779A (ja) Ｇｃｃを標的とする抗体及びキメラ抗原受容体並びにそれらの使用方法
CN120157769A (zh) 一种新型环肽构型、其文库制备方法及应用
Huhtinen ADVANCING ANTIBODY ENGINEERING
CN114245804A (zh) 修饰的人可变域
WO2019012015A1 (en) POTASIC CHANNEL INHIBITORS
Kym Engineered discoidin domain from factor VIII binds αvβ3 integrin with antibody-like affinity
BR112018013883B1 (pt) Método de triagem para membros de ligação que exibem atividade de ligação, método para produzir uma biblioteca de membros de ligação e método para produzir um membro de ligação

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment